Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on February 28, 2023, reporting events occurring on February 27, 2023. The filing primarily addresses the appointment of a new director and the expansion of the Board of Directors.
Key Financial Metrics
This filing does not report comprehensive financial results such as revenue, profit, cash flow, or debt for the reporting period. However, it discloses specific contract details regarding a related party transaction:
- Related Party Contract: Carle Health, a client of the Company, has a five-year contract for the Company's Solution commencing in December 2022.
- Historical Payments: Carle Health made payments of approximately $5.5 million to the Company in the year ended December 31, 2022.
- Projected Revenue Impact: The Company expects payments from Carle Health in the year ending December 31, 2023, to slightly exceed 5% of its projected revenue for that period.
Material Changes
The primary material change reported is the expansion of the Board of Directors from seven to eight members. Matthew Kolb was appointed to fill a newly created open Board seat, effective July 1, 2023. Mr. Kolb will serve as a Class I director until the 2026 annual meeting of stockholders.
Outlook, Risks, and Unusual Items
Management Commentary and Risks: The filing contains forward-looking statements regarding the director appointment, the client contract, and anticipated revenue. The Company notes that actual results may differ materially from expectations due to factors including changes under the client contract and financial performance. The Company does not intend to update these forward-looking statements.
Compensation and Relationships: Mr. Kolb will not receive compensation for his Board service other than reimbursement of out-of-pocket expenses. He is currently the Executive Vice President and Chief Operating Officer of Carle Health, a client of the Company. No family relationships exist between Mr. Kolb and other directors or executive officers.
Investor Verification Checklist
- Verify the total projected revenue for the year ending December 31, 2023, to confirm the significance of the Carle Health contract exceeding 5% of revenue.
- Review the Company's most recent Form 10-K and subsequent 10-Q filings for comprehensive financial performance data not included in this 8-K.
- Confirm the terms of the five-year contract with Carle Health to understand the billing structure and potential for future revenue fluctuations.
- Monitor the effective date of Mr. Kolb's appointment (July 1, 2023) and his tenure as a Class I director.